Corvus Stock: Soquelitinib Q1 Interim Futility Analysis AD Drug Advancement (NASDAQ:CRVS)
· seekingalpha.com
Corvus Pharma (CRVS) Strong Buy: soquelitinib PTCL & atopic dermatitis catalysts, key 2027 readouts, $215M cash to Q2 2028—read now.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...